Exploiting our knowledge of NF-κB signaling for the treatment of mammary cancer

Michael C. Haffner, Chiara Berlato, Wolfgang Doppler

Research output: Contribution to journalReview article

Abstract

Nuclear Factor-kappaB (NF-κB) has been implicated in the lobuloalveolar development of the mammary gland. In breast cancer its activation has been linked to tumor progression via stimulation of cell proliferation, pro-survival, and angiogenesis pathways and metastasis. Whether NF-κB activation in the immune system influences mammary cancer remains unclear. In addition to the constitutive activation frequently found in mammary carcinoma tissue, radio- and chemotherapeutic agents used in the treatment of mammary cancer can lead to activation of NF-κB. This effect has been postulated to contribute to the development of resistance to these agents and suggests the use of NF-κB inhibitors as sensitizers for therapy. The review describes principle targets and drugs used to inhibit NF-κB function and discusses future perspectives in the use of these inhibitors for the treatment of mammary cancer.

Original languageEnglish (US)
Pages (from-to)63-73
Number of pages11
JournalJournal of Mammary Gland Biology and Neoplasia
Volume11
Issue number1
DOIs
StatePublished - Jan 1 2006

    Fingerprint

Keywords

  • Apoptosis
  • Breast cancer
  • Chemosensitization
  • Metastasis
  • NF-κB
  • Proteasome

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this